Side Effects of Psychiatric Therapeutics Program
Overview
This program supports research to elucidate the biomedical and psychosocial risk factors for the development of treatment-emergent side effects of psychiatric therapeutics, and to develop interventions to predict, prevent and/or mitigate these side effects.
Areas of Emphasis
- Early-phase clinical studies of new medications targeting major mental illnesses or symptom domains now lacking adequate treatments.
- Studies integrating evaluation of mechanisms of therapeutic response to pharmacological agents with assessment of efficacy.
- Studies to predict treatment response and facilitate individualized pharmacological therapeutics.
- Clinical treatment studies integrating biomarkers with traditional clinical endpoints to validate the clinical utility of putative surrogate markers of treatment response.
- Studies to identify predictors of adverse effects of psychopharmacological agents and intervention development to mitigate these adverse effects.
- Studies of efficacy of novel somatic treatments or medical devices for the treatment of mental illness.
Contact
Mark Chavez, Ph.D.
Program Chief
6001 Executive Boulevard, Room 7101, MSC 9632
301-443-8942, mchavez1@mail.nih.gov
